Abstract
Prostate cancer (PCa) is the most commonly diagnosed malignant tumor in men and the second leading cause of cancer-related mortality. Despite the high long-term survival in localized prostate cancer, metastatic disease remains largely incurable even after intensive multimodal therapy. Even with immunotherapy, which has improved patient survival in many types of cancers, PCa results have b…